EBOS Group Limited (ASX:EBO)
Australia · Delayed Price · Currency is AUD 25.20
-0.42 (-1.64%)
Oct 17, 2025, 4:10 PM AEST
EBOS Group Revenue
In the fiscal year ending June 30, 2025, EBOS Group had annual revenue of 12.27 billion AUD, down -6.99%. EBOS Group had revenue of 6.28 billion in the half year ending June 30, 2025, with 3.02% growth.
Revenue
12.27B
Revenue Growth
-6.99%
P/S Ratio
0.42
Revenue / Employee
2.13M
Employees
5,770
Market Cap
5.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.27B | -922.16M | -6.99% |
| Jun 30, 2024 | 13.19B | 951.65M | 7.78% |
| Jun 30, 2023 | 12.24B | 1.50B | 14.00% |
| Jun 30, 2022 | 10.73B | 1.53B | 16.64% |
| Jun 30, 2021 | 9.20B | 437.35M | 4.99% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
EBOS Group News
- 6 months ago - UBS launches $NZ217m EBOS Group placement to fund acquisitions - The Australian Financial Review
- 8 months ago - Ebos Group Ltd (EBOSF) (Q1 2025) Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - GuruFocus
- 8 months ago - Half Year 2025 EBOS Group Ltd Earnings Call Transcript - GuruFocus